Back to Dashboard
VRTX · Healthcare

VERTEX PHARMACEUTICALS INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Weak — few signals

No standout activity across the feeds we track.

Hedge funds
52
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Limited info. VERTEX PHARMACEUTICALS INC is not currently in our model portfolio, but 9 tracked investors hold it. We're showing what we know from their latest 13F filings.
Market cap
$123.3B
Industry
Biotechnology
Exchange
NasdaqGS
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of…
9
Investors
0
New positions
2
Increasing
4
Decreasing
3
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Citadel Advisors
Trust weight: 1.0×
Increased +146%
% of portfolio
0.1%
Position change
+146%
0.1% of Citadel Advisors's portfolio
Millennium Management (Englander)
Trust weight: 1.0×
Increased +791%
% of portfolio
0.1%
Position change
+791%
0.1% of Millennium Management's portfolio
Tweedy Browne
Trust weight: 1.2×
Unchanged
% of portfolio
1.4%
Position change
—
1.4% of Tweedy Browne's portfolio
ARK Invest (Cathie Wood)
Trust weight: 1.3×
Unchanged
% of portfolio
0.1%
Position change
—
0.1% of ARK Invest's portfolio
Baillie Gifford & Co
Trust weight: 1.4×
Decreased −3%
% of portfolio
0.1%
Position change
−3%
0.1% of Baillie Gifford & Co's portfolio
Bridgewater Associates (Dalio)
Trust weight: 1.3×
Decreased −28%
% of portfolio
0.1%
Position change
−28%
0.1% of Bridgewater Associates's portfolio
Gotham Asset Mgmt (Greenblatt)
Trust weight: 1.1×
Unchanged
% of portfolio
0.0%
Position change
—
0.0% of Gotham Asset Mgmt's portfolio
AQR Capital Management
Trust weight: 1.0×
Decreased −11%
% of portfolio
0.0%
Position change
−11%
0.0% of AQR Capital Management's portfolio
Tudor Investment (Paul Tudor Jones)
Trust weight: 1.2×
Decreased −89%
% of portfolio
0.0%
Position change
−89%
0.0% of Tudor Investment's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to VERTEX PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell VERTEX PHARMACEUTICALS INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
© 2026 Bogen Capital  ·  Not financial advice  ·  Data delayed up to 135 days Methodology  ·  Contact  ·  API